Piramal Pharma Limited

NSE PPLPHARMA.NS

Piramal Pharma Limited EBIT Margin for the year ending March 31, 2024: 7.66%

Piramal Pharma Limited EBIT Margin is 7.66% for the year ending March 31, 2024, a 219.89% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Piramal Pharma Limited EBIT Margin for the year ending March 31, 2023 was 2.40%, a -88.12% change year over year.
Piramal Pharma Limited EBIT Margin for the year ending March 31, 2022 was 20.17%, a 7.68% change year over year.
Piramal Pharma Limited EBIT Margin for the year ending March 31, 2021 was 18.73%.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NSE: PPLPHARMA.NS

Piramal Pharma Limited

CEO	Mr. Peter Daniel DeYoung
IPO Date	Oct. 19, 2022
Location	India
Headquarters	507, Skyline Wealth Space
Employees	6,719
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Piramal Pharma Limited operates as a pharmaceutical company. It sells a portfolio of pharma products, as well as provides various pharma services, including injection, HPAPI, etc. The company was incorporated in 2020 and is based in Mumbai, India. Piramal Pharma Limited operates as a subsidiary of Piramal Enterprises Limited.

Key trends

Past 5 years